2022年初临床肿瘤学研究亮点
Research highlights of clinical oncology early 2022.
作者信息
Wu Kaichun
机构信息
Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
出版信息
Holist Integr Oncol. 2022;1(1):6. doi: 10.1007/s44178-022-00006-9. Epub 2022 Jul 5.
Abstract
Advance in clinical oncology is highly relied on development of cancer research and clinical trials. There has been ample evidence regarding the new therapeutic drugs, agents or techniques for the treatment of cancer. We did a broad literature search to catch the latest progress in the cancer therapy. Here is a brief review of the newly released results of clinical trials including surgical modalities, immune checkpoint blockade, chimeric antigen receptor T-cell (CAR T) therapy, antibody-drug conjugates and tumor vaccines, etc. Biomarkers or patient assessment of cancer therapy were also discussed.
摘要
临床肿瘤学的进展高度依赖于癌症研究和临床试验的发展。关于治疗癌症的新治疗药物、制剂或技术已有充分证据。我们进行了广泛的文献检索以了解癌症治疗的最新进展。以下是对新发布的临床试验结果的简要综述，包括手术方式、免疫检查点阻断、嵌合抗原受体T细胞（CAR T）疗法、抗体药物偶联物和肿瘤疫苗等。还讨论了癌症治疗的生物标志物或患者评估。
相似文献
1
Research highlights of clinical oncology early 2022.2022年初临床肿瘤学研究亮点
Holist Integr Oncol. 2022;1(1):6. doi: 10.1007/s44178-022-00006-9. Epub 2022 Jul 5.
2
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.三阴性乳腺癌免疫治疗的进展与展望
Front Oncol. 2022 Jun 20;12:919072. doi: 10.3389/fonc.2022.919072. eCollection 2022.
3
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.儿童和青少年癌症嵌合抗原受体T细胞药物开发儿科战略论坛：ACCELERATE与欧洲药品管理局合作，并由美国食品药品监督管理局参与。
Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25.
4
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤中的癌症免疫疗法
Front Oncol. 2018 Sep 10;8:351. doi: 10.3389/fonc.2018.00351. eCollection 2018.
5
Personalized Immuno-Oncology.个性化免疫肿瘤学。
Med Princ Pract. 2021;30(1):1-16. doi: 10.1159/000511107. Epub 2020 Aug 25.
6
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.黑色素瘤研究的未来展望：“黑色素瘤桥梁”会议报告。那不勒斯，2015年12月1日至4日
J Transl Med. 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y.
7
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.胶质母细胞瘤免疫治疗：现有策略的系统评价及进展展望。
Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037.
8
Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy.肺癌的免疫治疗：聚焦嵌合抗原受体（CAR）-T 细胞疗法。
Curr Probl Cancer. 2022 Feb;46(1):100791. doi: 10.1016/j.currproblcancer.2021.100791. Epub 2021 Sep 3.
9
Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.双特异性前列腺特异性膜抗原抗体与嵌合抗原受体T细胞疗法用于转移性去势抵抗性前列腺癌的治疗
Ther Adv Urol. 2023 Jun 15;15:17562872231182219. doi: 10.1177/17562872231182219. eCollection 2023 Jan-Dec.
10
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.免疫疗法在靶向多发性骨髓瘤骨髓微环境中的作用：一种不断发展的治疗策略。
Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6.
引用本文的文献
1
Cost-effectiveness of datopotamab deruxtecan in previously treated advanced nonsquamous NSCLC.达泊妥单抗德鲁替康在既往接受过治疗的晚期非鳞状非小细胞肺癌中的成本效益
Medicine (Baltimore). 2025 May 16;104(20):e42419. doi: 10.1097/MD.0000000000042419.
2
Breast cancer: pathogenesis and treatments.乳腺癌：发病机制与治疗方法
Signal Transduct Target Ther. 2025 Feb 19;10(1):49. doi: 10.1038/s41392-024-02108-4.
3
Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.癌症治疗中的抗体药物偶联物：作用机制与临床研究
MedComm (2020). 2024 Jul 28;5(8):e671. doi: 10.1002/mco2.671. eCollection 2024 Aug.
4
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer.多斯塔利单抗联合化疗用于原发性晚期或复发性子宫内膜癌的成本效益
Front Pharmacol. 2024 Jun 20;15:1391896. doi: 10.3389/fphar.2024.1391896. eCollection 2024.
本文引用的文献
1
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.瑞博西林联合来曲唑治疗晚期乳腺癌的总生存期。
N Engl J Med. 2022 Mar 10;386(10):942-950. doi: 10.1056/NEJMoa2114663.
2
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.低危甲状腺癌患者的甲状腺切除术不伴放射性碘治疗。
N Engl J Med. 2022 Mar 10;386(10):923-932. doi: 10.1056/NEJMoa2111953.
3
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌。
N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19.
4
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.阿替利珠单抗联合恩扎卢胺对比单独恩扎卢胺治疗转移性去势抵抗性前列腺癌：一项随机、3 期临床试验。
Nat Med. 2022 Jan;28(1):144-153. doi: 10.1038/s41591-021-01600-6. Epub 2022 Jan 10.
5
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.Relatlimab 和 Nivolumab 对比 Nivolumab 用于未经治疗的晚期黑色素瘤。
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
6
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.21 基因检测在淋巴结阳性乳腺癌中预测化疗获益。
N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1.
7
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
8
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.一项针对 IDO/PD-L1 免疫调节疫苗联合纳武利尤单抗治疗转移性黑色素瘤的 1/2 期临床试验。
Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9.
9
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.随机化试验：细胞减灭术治疗复发性卵巢癌。
N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294.
10
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.贝伐珠单抗治疗 von Hippel-Lindau 病相关肾细胞癌
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
Zotero 插件